Thus, we are confident that in the future, novel therapeutic protocols will be designed based on the combination of anti-HLA-G antibodies with anti-PD-1 (pembrolizumab, nivolumab) or anti-PD-L1 (avelumab, atezolizumab, durvalumab) antibodies, or inhibitors, in order to improve the clinical outcome of cancer patients. The gene discussed is HLA-G; the disease is cancer.